<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263507</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 721744-CS1</org_study_id>
    <nct_id>NCT03263507</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-PKK-LRx Administered Subcutaneously to Healthy Volunteers</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 721744, an Antisense Oligonucleotide Inhibitor of PKK, Administered Subcutaneously to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of
      IONIS-PKK-LRx administered subcutaneously to Healthy Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events that are related to treatment with IONIS PKK-LRx</measure>
    <time_frame>Up to 176 days</time_frame>
    <description>The safety and tolerability of multiple doses of IONIS PKK-LRx will be assessed by determining the incidence, severity, and dose relationship of adverse events that are related to treatment with IONIS PKK-LRx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma Concentration (Cmax) of IONIS PKK-LRx</measure>
    <time_frame>Up to 176 days</time_frame>
    <description>Maximum IONIS PKK-LRx plasma concentration, Cmax (ug/mL) will be assessed following SC administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak plasma Concentration (Tmax) of IONIS PKK-LRx</measure>
    <time_frame>Up to 176 days</time_frame>
    <description>Time to peak IONIS PKK-LRx plasma concentration, Tmax (hours) will be assessed following SC administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of IONIS PKK-LRx on plasma PKK concentration</measure>
    <time_frame>Up to 176 days</time_frame>
    <description>Effects of IONIS PKK-LRx on plasma PKK concentration after multiple doses of IONIS PKK-Lrx compared to baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>IONIS PKK-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of IONIS PKK-LRx administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sterile saline 0.9%)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calculated volume to match active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline .9%</description>
    <arm_group_label>Placebo (sterile saline 0.9%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS PKK-LRx</intervention_name>
    <description>Ascending single and multiple doses of IONIS PKK-LRx administered subcutaneously</description>
    <arm_group_label>IONIS PKK-LRx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have given written informed consent and be able to comply with all study
             requirements

          -  Healthy males or females aged 18-65 inclusive at the time of Informed Consent

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or post-
             menopausal

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

          -  BMI &lt;35 kg/m2

        Exclusion Criteria:

          -  Clinically-significant abnormalities in medical history including acute coronary
             syndrome, major surgery within 3 months of Screening, planned surgery that would occur
             during the study or physical examination or other screening results such as ECGs at
             Screening

          -  Clinically significant hematologic, chemistry, and urine abnormalities

          -  Treatment with another Study Drug, biological agent, or device within 4 weeks of
             Screening

          -  History of bleeding diathesis or coagulopathy

          -  Smoking &gt;10 cigarettes per day

          -  Considered unsuitable for inclusion by the Principal Investigator

          -  Current use of concomitant medications (including herbal or OTC medications) unless
             approved by Sponsor Medical Monitor

          -  Known history or positive test for HIV, hepatitis C or chronic hepatitis B

          -  Blood donation within 30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biopharma Services</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IONIS PKK-LRx</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

